Phase IV prospective, randomized, open with blind endpoints, parallel group study to evaluate the effect of Aliskiren on endothelial dysfunction in patients with essential hypertension

Trial Profile

Phase IV prospective, randomized, open with blind endpoints, parallel group study to evaluate the effect of Aliskiren on endothelial dysfunction in patients with essential hypertension

Completed
Phase of Trial: Phase IV

Latest Information Update: 11 Jul 2012

At a glance

  • Drugs Aliskiren; Ramipril
  • Indications Essential hypertension
  • Focus Pharmacodynamics
  • Acronyms ALISEI
  • Most Recent Events

    • 17 Jun 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top